Ainos Inc (AIMD)

Ainos Expands Smell AI Platform into Digital Breath Intelligence Through National Taiwan University Research ProgramJune 17, 2026 8:00 AM
ACCESS NewswireProgram expands Ainos' Smell AI platform from environmental intelligence into digital breath intelligence for emergency medicine researchHOUSTON, TX / ACCESS Newswire / June 17, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent digitization and Smell AI technologies, today announced a new research program with National Taiwan University ("NTU") to explore the use of Smell AI in emergency medicine.The program, titled "Rapid Diagnosis of Dyspneic Patients in the Emergency Department via AI-powered Electronic Nose Technology," will explore the use of Ainos' Smell AI platform to analyze volatile organic compounds ("VOCs") in exhaled breath. The goal is to study whether AI-driven breath-print analysis can help emergency physicians more quickly evaluate patients presenting with dyspnea, commonly known as shortness of breath.Ainos' Smell AI technology, powered by AI Nose and Smell Language Model, traces its roots to healthcare-focused R&D, where the need for non-invasive sensing, accuracy, and real-world validation helped shape the Company's core technology platform.This program differs from Ainos' existing National Taiwan University Hospital initiative by expanding Smell AI from healthcare environmental sensing into patient-level digital breath intelligence, studying whether exhaled VOC patterns can become machine-readable breath-print Smell ID for emergency medicine research.Dyspnea is one of the most common and difficult symptoms seen in emergency departments. Patients with acute exacerbation of chronic obstructive pulmonary disease ("AECOPD") and acute decompensated heart failure ("ADHF") can appear similar at first, although they often require different treatment pathways. The research program aims to develop and evaluate a Deep Dyspnea Differential system designed to analyze VOC-based breath prints and study whether those patterns may help differentiate AECOPD, ADHF, and non-disease control groups."Emergency dyspnea triage is a high-value clinical challenge where time and diagnostic clarity are critical," said Eddy Tsai, Chairman, President and Chief Executive Officer of Ainos. "AI Nose was originally developed with medical diagnostic applications in mind, where non-invasive sensing, accuracy, and real-world validation are essential. This research program brings that experience back into a high-value clinical setting and extends our Smell AI platform into digital breath intelligence. We believe this is an important step in advancing our broader vision of building Smell ID data and Smell Language Model capabilities across healthcare, industrial, and physical AI environments."The program is expected to include prospective enrollment, breath sampling from emergency department patients and control subjects, deep learning model training, and external validation against final clinical diagnoses. If successful, the research may contribute to a breath-print database for dyspnea and support future studies in emergency, outpatient, pre-hospital, and home-monitoring settings."This program reflects Ainos' platform strategy," added Mr. Tsai. "Across semiconductor manufacturing, healthcare infrastructure, robotics, and emergency breath analysis, our objective is to convert previously inaccessible scent and VOC signals into structured data for AI systems. Each real-world deployment can expand the data foundation for Smell AI."The research program is scheduled to run for one year, from July 1, 2026. The technology and workflow remain research-stage.About AI NoseAI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.About Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date. Visit media room https://ainos.suite.accessnewswire.com.Forward-Looking StatementsCertain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.Contact Information
Investor Relations
ir@ainos.comSOURCE: Ainos, Inc.View the original press release on ACCESS NewswireOriginal: Ainos Expands Smell AI Platform into Digital Breath Intelligence Through National Taiwan University Research Program

Ainos Releases 2026 Mid-Year CEO Letter to ShareholdersJune 8, 2026 8:00 AM
ACCESS NewswireBuilding the Olfactory Layer of Physical AIHighlighting Progress Across Semiconductor Manufacturing, Healthcare Infrastructure and Physical AI ApplicationsHOUSTON, TX / ACCESS Newswire / June 8, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent digitization and Smell AI technologies, today released its 2026 Mid-Year Letter to Shareholders from Chairman, President and Chief Executive Officer Eddy Tsai.2026 First Half HighlightsCommercial MomentumReported 499% year-over-year revenue growth during fiscal year 2025.Continued transforming Ainos from a biotechnology-focused company into a technology platform company centered on Smell AI and Environmental Intelligence.Updated the Company's industry classification to better reflect its technology-focused business model and long-term strategy.Semiconductor Industry ExpansionAdvanced commercial deployments, validation programs and proof-of-concept initiatives across semiconductor manufacturing and advanced packaging environments.Continued collaboration with one of the world's leading advanced semiconductor manufacturers and multiple strategic industry partners.Expanded industrial-scale Smell AI datasets supporting environmental intelligence and safety monitoring applications.Healthcare InfrastructureExpanded Smell AI beyond industrial environments into healthcare settings.Initiated collaborative research programs with National Taiwan University Hospital and MacKay Memorial Hospital.Advanced applications including emergency department congestion monitoring, respiratory infection risk assessment, environmental intelligence and healthcare facility safety management.Looking AheadDuring the second half of 2026, Ainos plans to focus on:Scaling commercial deployments.Expanding semiconductor industry adoption.Growing global Smell AI datasets.Advancing Smell Language Model development.Building foundational olfactory infrastructure for Physical AI.Letter to ShareholdersDear Shareholders, Partners and Supporters,Many people still describe Ainos as an electronic nose company, a sensor company or even a biotechnology company. While each description contains elements of truth, none fully captures what we are building.We believe the world is entering the next stage of artificial intelligence: Physical AI.AI can already see.
AI can already understand language.
AI can already reason.Yet one important capability remains largely absent: smell.Humans continuously use scent to understand their surroundings, identify risks, detect abnormalities and interpret environmental changes. Despite decades of technological progress, scent remains one of the last major categories of real-world information that has not yet been fully digitized.That is the challenge Ainos was created to address.We believe the next wave of AI will move beyond digital intelligence and into real-world intelligence.If vision is AI's eyes,
if voice is AI's ears,
and if reasoning is AI's brain,
then smell may become one of the most important missing senses of Physical AI.Our mission is not simply to build an electronic nose. Our mission is to build Smell AI, Smell Data and Smell Infrastructure. We believe these capabilities can enable scent to become machine-readable, analyzable and scalable.From Validation to Real-World DeploymentDuring the first half of 2026, Ainos continued advancing the commercialization of AI Nose and Smell AI technologies.In the semiconductor industry, we expanded deployment and validation initiatives with leading advanced semiconductor manufacturers, advanced packaging leaders and strategic industry partners. These efforts are helping establish some of the earliest industrial-scale Smell AI data networks.In healthcare, Ainos expanded Smell AI into clinical environments through collaborative research programs with National Taiwan University Hospital and MacKay Memorial Hospital. These initiatives focus on emergency department congestion monitoring, respiratory infection risk assessment, environmental awareness and healthcare facility safety management.Together, these programs demonstrate how Smell AI can move beyond the laboratory and into real-world environments.At the same time, we continue exploring opportunities in robotics and Physical AI systems. As intelligent machines move further into real-world environments, they will require more than vision, language and reasoning. They will require environmental awareness.In many situations, scent may provide one of the earliest signals of change.Building Long-Term ValueWe believe Ainos is evolving from a hardware company into a data and intelligence platform. We are building the long-term foundation of a platform that includes:Smell ID.Smell Datasets.Smell Language Models.Smell Foundation Models.Global Smell Intelligence Networks.Just as the value of leading technology companies extends far beyond their original products, we believe the long-term opportunity for Ainos extends beyond electronic nose devices.When people think about Smell AI, Digital Smell, Machine Olfaction and Physical AI Smell Infrastructure, we hope Ainos will be among the first names that comes to mind.Looking ForwardThe first half of 2026 was about proving that Smell AI could move beyond the laboratory and into the real world.The second half of 2026 will be about scaling that vision.We believe the future of Physical AI will require environmental awareness. We believe scent represents one of the earliest signals of change in the physical world. Ainos is building the infrastructure designed to help machines understand those signals.We are building the olfactory layer of Physical AI.On behalf of the entire Ainos team, I would like to thank our shareholders, customers, partners and employees for their continued trust and support.We remain committed to creating long-term value and advancing the future of Smell AI.Sincerely,Eddy Tsai
Chairman, President and Chief Executive Officer
Ainos, Inc.About AI NoseAI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.About Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date. Visit media room https://ainos.suite.accessnewswire.com.Forward-Looking StatementsCertain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.Contact Information
Investor Relations
ir@ainos.comSOURCE: Ainos, Inc.View the original press release on ACCESS NewswireOriginal: Ainos Releases 2026 Mid-Year CEO Letter to Shareholders

VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department OperationsJune 5, 2026 8:00 AM
ACCESS NewswireHOUSTON, TX / ACCESS Newswire / June 5, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today highlighted a recent report published by VASRO GmbH ("VASRO"), discussing the expansion of the Company's AI Nose platform into emergency department operations and the continued growth of its Smell ID data across diverse real-world environments.In the report, VASRO reviews Ainos' recently announced research program at one of Asia's leading academic medical centers, where AI Nose is being deployed within a live emergency department environment to evaluate environmental scent analysis for emergency department overcrowding early warning and respiratory infection risk analysis. The program is designed to generate more than 2,500 hours of emergency-department environmental data.According to the report, the initiative expands AI Nose beyond semiconductor manufacturing, industrial environments, and robotics into a new healthcare infrastructure application. VASRO notes that the deployment broadens the range of environments in which the platform is being evaluated while generating real-world scent data that contribute to the continued development of Ainos' Smell Language Model ("SLM").The report further highlights similarities between semiconductor manufacturing facilities and hospital emergency departments as highly dynamic environments where early detection of changing environmental conditions may provide operational value.VASRO highlighted the value of evaluating the technology within a live emergency department environment, providing an additional real-world source of scent data while broadening the range of environments in which the Company's Smell AI platform is being evaluated."We believe the value of Smell AI, powered by AI Nose, comes from its ability to operate across a growing range of real-world environments," said Eddy Tsai, Chairman, President and Chief Executive Officer of Ainos. "As we continue expanding AI Nose across industrial, healthcare infrastructure, and other environments, we are also expanding the Smell ID data that helps build Smell AI as a new layer of machine perception."The full VASRO report is available here: https://vasro.de/wp-content/uploads/2026/06/VASRO-GmbH_Update_Report_Ainos_Inc_06042026_EN.pdfAbout AI NoseAI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.About Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date. Visit media room https://ainos.suite.accessnewswire.com.Forward-Looking StatementsCertain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.Contact Information
Investor Relations
ir@ainos.comSOURCE: Ainos, Inc.View the original press release on ACCESS NewswireOriginal: VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations

Ainos Launches Smell AI Study at National Taiwan University Hospital for ER Overcrowding and Respiratory Infection Risk AnalysisJune 1, 2026 8:00 AM
ACCESS NewswireAI Nose Expands from Semiconductor Facilities into Frontline Healthcare InfrastructureHOUSTON, TX / ACCESS Newswire / June 1, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today announced the launch of a research program at National Taiwan University Hospital ("NTUH"), one of Asia's leading academic medical centers, to deploy AI Nose inside a live emergency department environment for intelligent environmental monitoring, ER overcrowding early warning, and respiratory infection risk analysis.The program aims to expand Smell AI, powered by AI Nose, inside a real-world emergency department environment and expands market opportunities beyond semiconductor and industrial environments into frontline healthcare infrastructure.The study, titled "Establishment of an Early Warning System for Emergency Department Overcrowding and Respiratory Infection Risk by Application of AI Electronic Nose for Intelligent Environmental Monitoring," will deploy AI Nose systems across waiting areas, treatment areas, and observation zones inside the NTUH emergency department.The systems will continuously analyze environmental scent patterns and broader environmental signals associated with crowd density, patient flow, waiting conditions, and respiratory infection-related environmental changes.Ainos designed the project to move beyond traditional volatile organic compound ("VOC") monitoring and build AI-powered environmental intelligence infrastructure for complex healthcare environments.Ainos believes that emergency departments represent some of the most operationally challenging environments in healthcare systems worldwide. Constant movement of patients, visitors, and medical staff continuously changes airflow, occupancy, and environmental conditions, while overcrowding and respiratory infection risks remain major operational and public health challenges.Using AI Nose, Ainos converts complex environmental scent and air-pattern signals into machine-readable digital data called "Smell ID." The Company will use that data to develop healthcare-specific environmental mapping and AI-driven risk models.The study will generate more than 2,500 hours of emergency department environmental data and support development of AI models designed to analyze:Emergency department overcrowding conditionsRelationships between crowd density and environmental changesRespiratory infection-related environmental signalsHigh-risk crowding pattern alertsPotential scalability across broader hospital environments"This project represents an important step toward AI-powered environmental intelligence infrastructure," said Eddy Tsai, Chairman, President, and Chief Executive Officer of Ainos."Our deployments in semiconductor facilities have taught AI Nose how to recognize abnormal environmental changes inside highly sensitive, high-risk environments. Emergency departments represent another highly complex real-world operating environment.""The challenge is not detecting a single environmental signal. The challenge is understanding how risk patterns evolve across an entire environment in real time.""We believe future hospitals will not only see and hear operational risks, but also gain the ability to detect environmental changes associated with those risks through Smell AI."Ainos recently expanded commercialization efforts for AI Nose across smart manufacturing environments, such as advanced semiconductor manufacturing. Through those deployments, the Company has accumulated operational experience in real-time monitoring, anomaly recognition, and environmental analysis in complex industrial settings.Ainos believes semiconductor fabs and emergency departments share important characteristics as high-density, high-sensitivity environments that require continuous monitoring and rapid situational awareness.This program marks a strategic expansion of AI Nose from Industrial Smell AI into Healthcare Smell AI and broader public-environment risk monitoring applications.Ainos believes Smell AI, powered by AI Nose, could become an important enabling capability across smart hospitals, public health systems, smart buildings, and future intelligent city infrastructure.The study will not involve individual patient diagnosis or collect images, voice recordings, or personally identifiable information. Researchers designed the project as a non-invasive environmental AI monitoring study focused on environmental-level pattern analysis.NTUH's Institutional Review Board ("IRB") approved the study. The study is scheduled to begin on June 1, 2026, and is expected to continue for approximately six months.About AI NoseAI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.About Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date. Visit media room https://ainos.suite.accessnewswire.com.Forward-Looking StatementsCertain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.Contact Information
Investor Relations
ir@ainos.comSOURCE: Ainos, Inc.View the original press release on ACCESS NewswireOriginal: Ainos Launches Smell AI Study at National Taiwan University Hospital for ER Overcrowding and Respiratory Infection Risk Analysis

VASRO Research Highlights Ainos AI Nose Commercialization Progress and Semiconductor Industry Shift Toward AI-Driven Environmental IntelligenceMay 20, 2026 8:00 AM
ACCESS NewswireHOUSTON, TX / ACCESS Newswire / May 20, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today highlighted a new research update published by VASRO GmbH discussing AI Nose, the Company's AI-powered scent digitization and Smell AI platform, and ongoing commercialization progress across semiconductor manufacturing, robotics integration, and healthcare infrastructure markets. The report notes that the Company is advancing initiatives intended to support potential second half 2026 revenue generation.The VASRO report characterizes Ainos' first quarter of 2026 as a "commercialization-build quarter." According to the report, Ainos continues progressing key initiatives involving approximately 1,400 AI Nose systems associated with a backend semiconductor manufacturing customer, separate front-end wafer fabrication qualification activities involving approximately 200 systems, and an additional 600-system partner commitment.The report further notes that Ainos has expanded AI Nose deployment and validation activities across multiple operating environments, including backend semiconductor manufacturing, front-end wafer fabrication, robotics integration, and healthcare infrastructure applications.In healthcare infrastructure environments, the report discusses initiatives involving power and electromechanical systems, gas and HVAC infrastructure, chemical-handling areas, and laboratory and MRI environments where real-time environmental monitoring and intelligent sensing may support operational awareness and infrastructure management.The VASRO report also discusses broader semiconductor industry trends toward predictive maintenance, AI-driven process control, real-time environmental monitoring, pollution-control optimization, and increasingly sensor-rich AI-enabled manufacturing environments. According to the report, these trends are aligned with the types of AI-powered environmental sensing, anomaly detection, and machine-readable environmental intelligence capabilities AI Nose is designed to support across industrial settings."We believe industrial environments are increasingly adopting real-time sensing, predictive monitoring, and AI-driven environmental analytics," said Eddy Tsai, Chairman, President and Chief Executive Officer of Ainos. "AI Nose is designed to convert volatile organic compound and scent signals into machine-readable Smell ID data, positioning Smell AI as a potential new AI perception layer across semiconductor manufacturing, robotics, healthcare infrastructure, and smart industrial environments. Our current focus remains on expanding deployments and advancing commercialization initiatives that we believe can support recurring revenue opportunities over time."The full VASRO report is available here: https://vasro.de/wp-content/uploads/2026/05/VASRO-GmbH_Update-Report_Ainos-Inc_05192026_EN.pdfAbout AI NoseAI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.About Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.Forward-Looking StatementsCertain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.Contact Information
Investor Relations
ir@ainos.comSOURCE: Ainos, Inc.View the original press release on ACCESS NewswireOriginal: VASRO Research Highlights Ainos AI Nose Commercialization Progress and Semiconductor Industry Shift Toward AI-Driven Environmental Intelligence

Ainos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure MarketsMay 13, 2026 4:30 PM
ACCESS NewswireHOUSTON, TX / ACCESS Newswire / May 13, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced financial results for the first quarter ended March 31, 2026 and provided a business update on recent execution progress for AI Nose across semiconductors and healthcare infrastructure applications .During the first quarter of 2026, Ainos continued executing its commercialization priorities for AI Nose across industrial infrastructure environments while continuing to expand its Smell ID datasets and refine its Smell Language Model ("SLM") through deployment and pilot activities."Our first quarter progress reflects a continued transition from validation activities toward broader enterprise-level infrastructure deployment readiness," said Eddy Tsai, Chairman, President and CEO of Ainos. "We believe the operational milestones achieved during the quarter has strengthened the foundation for future scalable commercialization of Smell AI - powered by AI Nose.""In addition to our progress in semiconductor environments, we are expanding AI Nose deployment into healthcare infrastructure settings, including hospital utility systems, laboratory environments, HVAC-related monitoring, MRI-related environments, and critical infrastructure safety applications. We believe this represents an important long-term application category for AI-driven environmental intelligence, by enabling continuous monitoring, anomaly awareness, and operational stability for hospital operation," Mr. Tsai concluded.Christopher Lee, Chief Financial Officer of Ainos, added, "During the first quarter, we strengthened our balance sheet and liquidity position through the previously announced NT$90 million (approximately US$2.8 million) financing arrangement while maintaining operating discipline as we advanced commercialization activities. Reported operating expenses declined approximately 30% year-over-year to approximately US$2.28 million.""Revenue during the quarter reflected the Company's ongoing transition toward industrial and infrastructure-focused AI Nose deployments, which remain in earlier stages of commercialization and validation. We believe our current execution priorities will help support broader revenue generation opportunities in the second half of 2026," Mr. Lee added.First Quarter 2026 and Recent Operational HighlightsContinued deployment activities associated with the previously announced approximately three-year $2.1 million AI Nose commercial arrangement in backend semiconductor manufacturing environments, targeting approximately 1400 AI Nose systemsInitiated pilot and validation activities in selected front-end semiconductor environmentsExpanded industrial commercialization initiatives through a distribution partnership supporting front-end semiconductor opportunitiesContinued robotics integration and pilot activities involving robotic and quadruped systemsContinued development of Smell ID datasets and Smell Language Model capabilities through deployment and pilot activitiesContinued optimization of AI Nose's near-threshold sensing and pattern-recognition capabilities through ongoing deployment and validation activities, supporting earlier identification of environmental anomalies across customer environmentsThe Company believes that enterprise adoption of AI-driven environmental intelligence technologies is typically driven by structured implementation roadmap with phased validation, infrastructure integration, and staged deployment. Ainos is aligning its commercialization strategy with these anticipated enterprise adoption patterns as it advances AI Nose across semiconductor, healthcare infrastructure, robotics, and industrial markets.Ainos remains focused on execution, deployment readiness, Smell ID dataset expansion, Smell Language Model development, and strategic commercial expansion, supporting its long-term objective of advancing AI Nose as a scalable Smell AI platform for real-world infrastructure environments.About AI NoseAI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.About Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.Forward-Looking StatementsCertain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.Contact Information
Investor Relations
ir@ainos.comAinos, Inc.
Condensed Consolidated Balance Sheets March 31, December 31, 2026 2025 (Unaudited) Assets Current assets: Cash and cash equivalents $2,841,422 $417,353 Accounts receivable 23 22 Inventory, net 315,643 295,565 Other current assets 362,527 425,859 Total current assets 3,519,615 1,138,799 Intangible assets, net 18,110,834 19,226,003 Property and equipment, net 290,078 343,281 Other assets 161,056 163,025 Total assets $22,081,583 $20,871,108 Liabilities and Stockholders' Equity Current liabilities: Contract liabilities $350,000 $350,000 Convertible notes payable - Related parties - current 2,000,000 - Loan payable to related parties 2,812,940 - Accrued expenses and others current liabilities 1,183,539 728,683 Total current liabilities 6,346,479 1,078,683 Convertible notes payable - Related parties - noncurrent 9,000,000 11,000,000 Other long-term liabilities 1,043,158 1,229,843 Total liabilities 16,389,637 13,308,526 Commitments and contingencies Stockholders' equity: Preferred stock, $0.01 par value; 50,000,000 shares authorized; none issued and outstanding as of March 31, 2026 and December 31, 2025 - - Common stock, $0.01 par value; 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025, 7,266,011 and 6,982,675 shares issued and 6,106,011 and 5,822,675 shares outstanding as of March 31, 2026, and December 31, 2025, respectively 72,660 69,827 Treasury stock, at cost (1,160,000 shares held as of March 31, 2026 and December 31, 2025) (1,972,000) (1,972,000)Additional paid-in capital 77,833,141 77,234,374 Accumulated deficit (69,980,128) (67,520,328)Accumulated other comprehensive loss (261,727) (249,291)Total stockholders' equity 5,691,946 7,562,582 Total liabilities and stockholders' equity $22,081,583 $20,871,108 Ainos, Inc.
Condensed Consolidated Statements of Operations
(Unaudited) Three months ended March 31, 2026 2025 Revenues $161 $106,207 Cost of revenues (763) (18,233)Gross profit (loss) (602) 87,974 Operating expenses: Research and development 1,689,860 1,724,084 Selling, general and administrative 593,185 1,526,761 Total operating expenses 2,283,045 3,250,845 Loss from operations (2,283,647) (3,162,871) Non-operating (expenses) income, net: Interest expense (176,876) (180,445)Other income, net 723 57,294 Total non-operating expenses, net (176,153) (123,151) Net loss before income taxes (2,459,800) (3,286,022)Provision for income taxes - - Net loss $(2,459,800) $(3,286,022)SOURCE: Ainos, Inc.View the original press release on ACCESS NewswireOriginal: Ainos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets

Ainos Shares Rise 5% on Push Into Healthcare AIApril 17, 2026 8:35 AM
IH Market News
Ainos Inc. (NASDAQ:AIMD) shares climbed 5% in premarket trading on Monday after the company unveiled plans to expand its smell-based AI technology into healthcare infrastructure.The rollout will target environmental monitoring and safety applications across hospital power systems, HVAC networks, chemical handling areas, and clinical laboratory environments, including MRI facilities. This marks a strategic shift beyond Ainos’ traditional focus on semiconductor and industrial use cases.At the core of the offering is the company’s AI Nose platform, which combines sensor arrays with proprietary algorithms to detect scents and translate analog signals into structured data via its Smell ID system. The platform also incorporates a Smell Language Model designed to analyze and classify scent patterns over time.A third-party report from VASRO GmbH noted that the technology enables scent signals to be converted into machine-readable data for environmental monitoring. The report highlighted 2026 as a key scaling year for Ainos as it moves toward broader deployment and revenue generation across multiple industries.“We are building Smell AI-powered by AI Nose-as a new layer of AI infrastructure that enables machines to sense, learn, and predict invisible scent signals,” said Eddy Tsai, Chairman, President and CEO.The company said it plans to deploy the technology using a service-based model for its scent detection solutions.Ainos stock price

Original: Ainos Shares Rise 5% on Push Into Healthcare AI

The Wall Street Journal Highlights Emerging "Smell AI" - Ainos Advances Commercial Deployment in Semiconductor EnvironmentsMarch 19, 2026 8:00 AM
ACCESS NewswireAs AI expands beyond vision and language, Ainos advances commercial deployment of AI Nose in industrial environments-positioning the Company at the forefront of this emerging categoryHOUSTON, TX / ACCESS Newswire / March 19, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform digitizing scent as a native data language for artificial intelligence, today highlighted its inclusion in The Wall Street Journal article "The E-Nose Knows: AI Learns to Smell," which underscores the emergence of AI capable of sensing and interpreting smell-expanding beyond traditional modalities such as vision, speech, and language.The article describes how AI-powered electronic nose ("E-Nose") systems are being applied across healthcare diagnostics, environmental monitoring, and industrial settings, including semiconductor manufacturing. The report also references Ainos among companies advancing AI smell technology.Ainos Perspective: Digital Olfaction as an Emerging AI Data FrontierAs highlighted in the report, smell-based AI remains at an early stage of development-comparable to computer vision decades ago-with potential applications spanning disease detection through breath analysis, industrial monitoring, and safety systems.Ainos believes digital olfaction represents a multi-year growth opportunity, with scent emerging as a new AI data modality. As computer vision evolved into a ubiquitous technology and a large market over time, AI-driven scent sensing is at the beginning of a similar adoption curve, supported by the development of scalable "Smell Data" and "Smell ID" frameworks.AI Nose, a trainable AI olfaction platform, originated in healthcare applications requiring high precision and sensitivity in detecting complex scent patterns. This technical foundation supports expansion into industrial and robotic environments, where continuous, real-time chemical sensing may enable predictive monitoring, automation, and safety improvements.Advancing Commercial Deployment in Semiconductor EnvironmentsAinos has initiated early-stage commercial deployment of AI Nose in semiconductor manufacturing environments, where ultra-clean conditions, and precise chemical control are essential.The Company is executing a signed deployment of 1,400 AI Nose systems in backend semiconductor environments. This deployment represents the initial phase of a broader roadmap targeting up to 20,000 systems.In parallel, Ainos is pursuing validation in front-end wafer fabrication environments with approximately 200 AI Nose systems, alongside early integration into robotic and quadruped inspection platforms.These activities signal the early stage of potential scaled adoption of AI-driven scent sensing in industrial environments.CEO CommentaryEddy Tsai, Chairman, President and CEO of Ainos, said:"Artificial intelligence is evolving from understanding what we see and hear to interpreting what we smell.We are at the early stage of this transition. At Ainos, we are moving beyond development into initial commercial deployment in industrial environments, including semiconductor-related settings.Semiconductor adoption is an important starting point, and we are expanding into robotics, smart manufacturing, and healthcare, where real-time chemical intelligence may become increasingly important. Our focus is on scaling deployments, building recurring revenue streams, and developing the data infrastructure that will support the next generation of Smell AI."Looking AheadAinos will continue expanding validation and deployment of its AI Nose platform across semiconductor and other industrial sectors, while advancing its SmellTech ecosystem, including data standardization, AI modeling, and scalable infrastructure.The Company believes that execution in real-world environments and expansion of recurring deployment models will be key drivers of long-term value creation.About Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.Forward-Looking StatementsCertain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.Contact InformationAinos IR
ir@ainos.comSOURCE: Ainos, Inc.View the original press release on ACCESS NewswireOriginal: The Wall Street Journal Highlights Emerging "Smell AI" - Ainos Advances Commercial Deployment in Semiconductor Environments

Ainos Expands AI Nose Validation in Front-End Wafer Fabs with 200 Targeted Deployments in Q1 2026March 9, 2026 8:30 AM
ACCESS NewswireCompany affirms execution milestones, subscription activation roadmap, and long-term infrastructure vision remain unchanged despite market volatilityHOUSTON, TEXAS / ACCESS Newswire / March 9, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced continued validation testing of its AI Nose platform within advanced semiconductor front-end wafer fabrication environments.As part of this qualification phase, Ainos plans to install approximately 200 AI Nose systems across targeted front-end facilities in the first quarter of 2026 for technical validation. These deployments would set the foundation for commercial integration in front-end wafer fabrication facilities, subject to customer review and formal commercial approval.Front-end wafer fabrication represents one of the most demanding industrial environments globally, requiring precise chemical process control and continuous cleanroom monitoring. Ainos believes the expanded validation reflects growing interest in integrating scent intelligence into semiconductor manufacturing systems.This front-end initiative builds on Ainos' broader deployment roadmap within the semiconductor ecosystem. Ainos is also executing Phase 1 deployment of 1,400 AI Nose systems with its back-end semiconductor customer. That phase represents approximately $2.1 million in total value under a three-year subscription framework and targets completion in the second quarter of 2026.The broader roadmap contemplates deployment of up to 20,000 AI Nose systems across the back-end customer's facilities, subject to technical validation and contractual conversion. If fully executed, the program could approach $10 million in annual subscription value."Front-end fabrication sets a high technical bar," said Eddy Tsai, Chairman, President and Chief Executive Officer of Ainos. "Our disciplined validation efforts support long-term integration of scent intelligence across the semiconductor value chain. Market volatility does not alter our execution milestones, subscription activation roadmap, or long-term infrastructure vision. Our operational progress and recurring revenue activation will define long-term shareholder value."About AI NoseAI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.About Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.Forward-Looking StatementsCertain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.Contact Information
Feifei Shen
ir@ainos.comSOURCE: Ainos, Inc.View the original press release on ACCESS NewswireOriginal: Ainos Expands AI Nose Validation in Front-End Wafer Fabs with 200 Targeted Deployments in Q1 2026

Ainos Issues Shareholder Letter on Phased AI Nose Deployment of Up to 20,000 Systems and Scalable Recurring Revenue OpportunityMarch 2, 2026 8:30 AM
ACCESS NewswireHOUSTON, TEXAS / ACCESS Newswire / March 2, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today issued the following letter from Chairman, President and Chief Executive Officer Eddy Tsai to shareholders, outlining the recurring revenue opportunity under the phased deployment framework of up to 20,000 AI Nose systems, and ongoing validation within advanced front-end semiconductor fabrication environments.To Our Shareholders,I'm proud to share that the AI Nose platform is transitioning from validation-stage pilots into structured industrial deployment.The confirmed initial order of 1,400 AI Nose systems activates recurring subscription revenue under a three-year service structure totaling approximately $2.1 million.This milestone marks our progression from proof-of-concept validation to revenue-generating implementation within semiconductor manufacturing environments. This also reflects our vision to expand AI Nose from healthcare into the broader industrial market.The broader roadmap contemplates phased deployment of up to 20,000 AI Nose systems across customer facilities. If fully executed over time, this framework could support annual order values approaching $10 million. Advancement into subsequent phases remains subject to staged technical validation and formal contractual conversion with our customer.Platform Economics and Recurring Revenue ModelWe are building AI Nose into a scent intelligence platform, scalable across a broad range of industries, spanning from healthcare to industrials. Our commercial architecture integrates four core components:Hardware deployment at the edgeSubscription-based analytics and monitoringContinuous AI model optimizationMulti-site scalability across industrial environmentsThis layered structure aims to support recurring revenue visibility while expanding operating leverage as deployments scale. As additional systems come online, subscription activation and data-driven model refinement are expected to further reinforce the platform's long-term economic profile.Semiconductor Front-End ValidationIn parallel, AI Nose is undergoing validation testing within advanced semiconductor front-end fabrication facilities - among the most technically demanding industrial environments in the world.These evaluations will set the foundation for commercial integration in advanced wafer fabrication facilities. Successful validation would expand our industrial integration opportunities within capital-intensive wafer fabrication environments.We remain focused on disciplined execution, subscription activation, and scalable infrastructure expansion as we position scent as the next AI token - advancing the smell language model (SLM), strengthening Smell ID libraries, and building SmellTech, powered by AI Nose, as a foundational sensing infrastructure for industrial AI systems.Sincerely,Eddy TsaiChairman, President & Chief Executive OfficerAinos, Inc.About AI NoseAI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.About Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.Forward-Looking StatementsCertain statements in this letter are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.Contact Information
Feifei Shen
ir@ainos.comSOURCE: Ainos, Inc.View the original press release on ACCESS NewswireOriginal: Ainos Issues Shareholder Letter on Phased AI Nose Deployment of Up to 20,000 Systems and Scalable Recurring Revenue Opportunity

Ainos Activates Industrial-Scale Deployment Roadmap of Up to 20,000 Units, Advancing AI Infrastructure Integration in Semiconductor Production EnvironmentsFebruary 23, 2026 8:30 AM
ACCESS NewswireHOUSTON, TEXAS / ACCESS Newswire / February 23, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced the activation of a phased industrial deployment roadmap under a strategic framework that contemplates the installation of up to 20,000 AI Nose units within semiconductor manufacturing environments.Phased Expansion Framework within Back-end Semiconductor EnvironmentsThe framework under a Memorandum of Understanding with ASE Technology Holding Co., Ltd. ("ASEH") outlines a multi-phase expansion strategy designed to integrate digital olfaction, powered by the AI Nose platform, into ASEH's semiconductor packaging and testing facilities.Ainos is executing the first phase of deployment that includes:confirmed order of 1,400 AI Nose units under a three-year subscription structure totaling approximately $2.1 millionAinos has received $350,000 in customer deposit paymentsAinos is targeting to complete the first phase deployment by the end of Q2 2026.Following phase one:Phase two contemplates deployment of 5,000 AI Nose unitsPhase three contemplates deployment of up to 15,000 AI Nose unitsAdvancement into subsequent phases remains subject to milestone validation and contractual progression under the strategic framework.Expansion into Advanced Front-End Semiconductor FabsIn parallel, Ainos is deploying AI Nose within advanced front-end semiconductor wafer fabrication facilities for validation testing. These deployments are part of technical qualification and remain subject to customer review and formal commercial approval prior to potential conversion into revenue-generating programs."Industrial AI is evolving toward multi-sensory infrastructure," said Eddy Tsai, Chairman, President and CEO of Ainos. "I believe digital olfaction represents a missing intelligence layer inside automated environments. We are executing a disciplined roadmap to integrate scent intelligence into semiconductor operations through scalable, recurring deployment models."About AI NoseAI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.About Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.Forward-Looking StatementsCertain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.Contact Information
Feifei Shen
ir@ainos.comSOURCE: Ainos, Inc.View the original press release on ACCESS NewswireOriginal: Ainos Activates Industrial-Scale Deployment Roadmap of Up to 20,000 Units, Advancing AI Infrastructure Integration in Semiconductor Production Environments

AIMD................................https://stockcharts.com/sc3/ui/?s=AIMD&p=w&b=5&g=0&id=p86431144783

Water Tower Research Highlights Mirle Partnership Fueling Ainos' Robotics Scale-Up and SmellTech ExpansionFebruary 5, 2026 8:00 AM
ACCESS NewswireAI Nose integration positions robotics application as a scalable growth engineMirle partnership expands SmellTech robotics into industrial environmentsHOUSTON, TEXAS / ACCESS Newswire / February 5, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced that Water Tower Research ("WTR") has published a report highlighting Ainos' expanding robotics opportunity and its strategy to scale the AI Nose platform across industrial and robotic applications, following the partnership with Mirle Automation Corporation ("Mirle").Key Highlights from the Report:Mirle Partnership Broadens AI Nose Robotics Applications: The partnership with Taiwan-based Mirle extends Ainos' robotics presence from commercial buildings and public infrastructures into industrial environments, which aligns with Ainos' other industrial programs. Mirle is a leading intelligent factory automation and robotics provider with more than 36 years of experience and deep exposure to semiconductor manufacturing and logistics automation. The company is scaling AI robotics platforms, including humanoid and quadruped systems, leveraging NVIDIA Omniverse for digital twin simulation and supported by a dedicated component supply chain.Robot Integration Expands AI Nose Access to Industrial and Security Environments: Integrating AI Nose into Mirle's mobile and quadruped robotic platforms enables deployment in demanding environments such as semiconductor fabs, advanced manufacturing facilities, community safety patrols, and border security. These settings require continuous monitoring and early detection of gas leaks, chemical anomalies, and volatile organic compounds ("VOCs") that vision or audio-based systems cannot identify.Scent Intelligence Adds a New Dimension to Robotic Awareness: AI Nose adds scent intelligence as a complementary sensing capability alongside Mirle's existing vision and audio, enabling robots to interpret chemical signals in real time. This additional perception dimension supports new use cases in safety monitoring, inspection, and autonomous operations across complex physical environments.Robotics Deployments Strengthen the Data Flywheel and Platform Scalability: As Ainos progresses from pilot programs toward broader deployment, embedding scent as a native data language directly into robotic hardware expands real-world data collection. Growing robotic adoption is expected to strengthen the Smell ID library, reinforce the data flywheel, and support scalable platform execution across industrial ecosystems."As robotics evolves toward greater autonomy, it becomes a natural extension of our AI Nose in complex industrial environments," said Eddy Tsai, Chairman, President, and CEO of Ainos, Inc. "Partnering with Mirle allows us to integrate scent intelligence directly into advanced robotic systems, expanding how AI interprets real-world signals and broadening the reach of our SmellTech across industrial applications."Read the Full Water Tower Research Report Here: https://www.watertowerresearch.com/doc?docID=UR_AIMD_02032026About AI NoseAI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.About Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.Forward-Looking StatementsCertain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.Contact Information
Feifei Shen
ir@ainos.comSOURCE: Ainos, Inc.View the original press release on ACCESS NewswireOriginal: Water Tower Research Highlights Mirle Partnership Fueling Ainos' Robotics Scale-Up and SmellTech Expansion

Water Tower Research Fireside Chat with Ainos: AI Nose Powering SmellTech Expansion and Scalable Value CreationFebruary 4, 2026 8:00 AM
ACCESS NewswireAI Nose advances through a dual-engine architecture, enabling scalable deploymentsIndustrial and semiconductor deployments broaden Ainos' commercial footprintRobotics momentum accelerates data flywheel growth and commercial scale-up in 2026HOUSTON, TEXAS / ACCESS Newswire / February 4, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced that Water Tower Research ("WTR") has published a report highlighting Ainos' SmellTech expansion, its value-creation strategy supported by a dual-engine architecture, and priorities for scaled execution in 2026. The report draws insights from a management fireside chat on January 26, 2026.Key Highlights from the Report:AI Nose advances as a foundational AI perception platform for digital olfaction: Ainos is positioning AI Nose as a core platform that converts scent into standardized, machine-readable Smell IDs and trains a proprietary Smell Language Model ("SLM"). Built on 13 years of high-precision healthcare development, the platform enables AI systems to interpret complex real-world environments through smell and supports expansion into continuous, high-throughput industrial applications.Dual-engine architecture supports scalable intelligence and recurring value creation: Ainos is positioned to control the physical sensing hardware and real-world data generation, while its wholly owned subsidiary, ScentAI, is positioned to deliver intelligence as a service. This structure is designed to support scalable deployments, recurring subscription economics, and long-term stewardship of proprietary smell data as the platform expands.Deployments in front-end and back-end semiconductors to anchor AI Nose expansion as a cross-stage intelligence platform: Ainos has secured multi-year semiconductor back-end orders totaling approximately $2.1 million for about 1,400 AI Nose units, marking commercial expansion into higher-volume industrial environments. Building on this foundation, partnerships with Trusval Technology and Topco Scientific extend deployments upstream into front-end wafer fabrication, expanding AI Nose's presence across both front-end and back-end semiconductor operations and supporting broader industrial scale-up.Robotics adoption accelerates real-world data compounding into 2026: Growing momentum in robotics, supported by pilot programs and a technology partnership with Taiwan-based Mirle Automation Corporation, expands AI Nose into autonomous and robotic systems. These deployments are expected to generate continuous real-world scent data, strengthen the Smell ID library, reinforce the data flywheel, and support long-term platform compounding."AI Nose is scaling as an AI perception platform that enables machines to understand the physical world through scent," said Eddy Tsai, Chairman, President, and CEO of Ainos, Inc. "As deployments expand across semiconductors and robotics, our dual-engine architecture supports data compounding, recurring value creation, and long-term scalability as smell becomes a native data layer for AI."Read the Full Water Tower Research Report Here: https://www.watertowerresearch.com/doc?docID=MS_AIMD_01222026About AI Nose
AI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.About Ainos, Inc.
Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.Contact Information
Feifei Shen
ir@ainos.comSOURCE: Ainos, Inc.View the original press release on ACCESS NewswireOriginal: Water Tower Research Fireside Chat with Ainos: AI Nose Powering SmellTech Expansion and Scalable Value Creation

AIMD. On the move

AIMD...........................................a/h

AIMD...$2.58...Post Split...🥳Micro Float now...

Smelling someSmaller hits .50s

Sounds positive...
Jack Lu, Head of Corporate Development at Ainos, appeared on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss Ainos' disruptive AI smelltech platform AI Nose. The company is pioneering an AI-powered smelltech solution using its proprietary AI Nose technology, which digitizes scent into Smell ID, with broad application spanning from point-of-care diagnostics, robotics and industrials.
S: wdhn.com/business..

More related news..
Ainos and ugo to Develop the World's First Robot With a Sense of Smell..

About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies.

More related news..
Ainos and ugo to Develop the World's First Robot With a Sense of Smell..

About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies.

Ainos Forms Partnership with ASE's Key Site to Power AI-Driven SmellTech in Semiconductor Smart Manufacturing


Wed, April 30, 2025 at 3:12 PM GMT+3 4 min read


Expanding AI Nose's Commercial Opportunity for Smarter, Safer, and More Sustainable Factories


SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 30, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-driven scent digitization, has announced it has formed a strategic partnership with ASE Chung Li ("ASECL") - a key site of Advanced Semiconductor Engineering, Inc., the world's leading provider of semiconductor assembly and test services. This new milestone expands the joint effort to power AI scent digitization in smart manufacturing. Under a legally binding Memorandum of Understanding (MOU), Ainos and ASECL aims to first optimize AI Nose for ASECL's environment, then strategize to deploy AI Nose in ASECL's operation.


ASECL, a member of the ASE Group, delivers comprehensive semiconductor manufacturing services, including engineering test, package design, IC assembly, wafer probing, final test, and design manufacturing services (DMS).



Unlocking a New Dimension in Smart Manufacturing

Despite the growing sophistication of semiconductor fabs, airborne VOCs (volatile organic compounds) remain a largely untapped source of process insight. These compounds can subtly impact yield, equipment health, and worker safety. Ainos' AI Nose transforms VOC patterns into real-time "Smell ID" data-enabling intelligent monitoring, predictive analytics, and ESG compliance at scale.


How AI Nose Will Enhance Smart Factory Operations:

Real-Time Air Quality Monitoring for Safer Work Environments

AI-Driven Predictive Maintenance & Energy Efficiency

Precision Process Control & Yield Optimization

Strengthening ESG Compliance & Sustainable Manufacturing



About Ainos, Inc.

Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name "Ainos" combines "AI" and "Nose" to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.


About ASE

Advanced Semiconductor Engineering, Inc. (ASE), a member of ASE Technology Holding Co., Ltd. (NYSE: ASX, TAIEX: 3711) is the leading global provider of semiconductor manufacturing services in assembly and test. Alongside a broad portfolio of established assembly and test technologies, ASE is also delivering innovative VIPack™, advanced packaging, and system-in-package solutions to meet growth momentum across a broad range of end markets, including AI, automotive, 5G, high-performance computing, and more. To learn about our advances in SiP, fanout, MEMS and sensor, flip chip, and 2.5D, 3D and TSV technologies, all ultimately geared towards applications to improve lifestyle and efficiency, please visit: ASE Website, or follow ASE on LinkedIn & X: @aseglobal.


https://finance.yahoo.com/news/ainos-forms-partnership-ases-key-121200362.html

$AIMD " Ainos' AI Nose system integrates a high-precision gas sensor array, real-time signal processing, and advanced AI algorithms to digitize and identify a wide range of volatile organic compounds (VOCs), or scents, into Smell IDs. This "Smell ID" is then used to detect odors and environmental conditions in a way that mirrors human olfaction. This installation represents the first time the technology has been embedded in a commercial-grade humanoid robot platform for real-world application. "

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/ainos-and-ugo-complete-first-robotic-smell-integration-in-japan-1017379

$AIMD Water Tower Research Highlights Ainos' AI Nose Expansion into Robotics and Semiconductor Manufacturing - Smell ID Is Scaling
https://finance.yahoo.com/news/water-tower-research-highlights-ainos-120000160.html

Ainos to Participate in Fireside Chat with Water Tower Research on April 8, 2025
https://finance.yahoo.com/news/ainos-participate-fireside-chat-water-210000274.html

AIMD...50s clearing here...🥳

Great to hear you and family are doing well,God bless and rock 🎸 on!

Nice grab...I added today as well...🥳

things are ok, i took a…

…

break for several months from trading, but im back.

Yes I remember,great to hear from you!
Hope all is well with you!

hey vette, remember me? I was….

…

chatting with you, maybe a couple years ago, or so, about your ihub name and told you that i had an 80 vette. i fixed it up and put it in car shows years ago, that was fun. sold it after a couple years but it was fun and got lots of looks.

anyway, hello again.

hi georgie and vette, i grabbed …..

…

some as well today.

Yup...been on it for a while now...🥳

Chart set up well,news of ai smelling chips,possible promo success with water tower research news started,4.8M float,15m o/s,69%insiders(none sold),float 5% short,5 PRs in last 8 days,I like the low risk with it back to where it took off from last time

As of March 7, 2025, there were issued and outstanding 15,433,257 shares of the registrant’s common stock, par value $0.01, which is the only class of common or voting stock of the registrant.

10K. weekend read. Pretty powerful news on this today
https://www.sec.gov/ix?doc=/Archives/edgar/data/1014763/000149315225009568/form10-k.htm

AIMD...59s clearing here....🥳

georgie18

Member Level
Re: georgie18 post# 672095

Thursday, January 23, 2025 12:38:56 PM

Post#
672148
of 676547
georgie18

Member Level
Re: georgie18 post# 388352

Thursday, January 23, 2025 9:28:06 AM

Post#
388939
of 388960
AIMD...70s adding here...🥳Loading under $1...

georgie18

Member Level
Re: georgie18 post# 670590

Friday, January 10, 2025 1:11:43 PM

Post#
671056
of 672094
AIMD...69...Hit $1 today...🥳

georgie18

Member Level
Re: georgie18 post# 388090

Monday, January 06, 2025 2:47:49 PM

Post#
388099
of 388351
AIMD...80s clearing here...🥳

georgie18

Member Level
Re: None

Monday, January 06, 2025 1:05:23 PM

Post#
670559
of 670589
AIMD...74s clearing here...🥳

Nice bit of news...thanks...🥳

sure: https://www.otcmarkets.com/stock/AIMD/news/story?e&id=3164503

Link please...🥳

nice news today

Lol...we vshall see...🥳

.73 Hidden treasure for those with patience $10 stock in future. Adds a dimension for robots ..smell and sniff then they can takeover a new world with 80% unemployment..lol

Moving up a bit...🥳holding...

.70 Eyes and ears ..head and toes from .60s looking good ..Patience pays once again 

$AIMD Key Highlights from the Report: AI Nose Programs and Strategic Milestones for 2025

AI Nose Technology: Ainos' Flagship Innovation

Robotics Integration: WTR noted that Ainos's strategic focus on positioning its AI Nose technology as a critical sensory enhancement for robotics and humanoid applications. The Company is actively seeking partnerships to integrate olfactory capabilities, addressing a pivotal gap in robot functionality.

Smart Manufacturing: In collaboration with Japanese partners, Ainos has developed a Volatile Organic Compounds ("VOC") sensing program with nearly 80% accuracy in identifying 22 VOCs across 761 test samples at semiconductor factories. WTR highlighted Ainos' plans for mass production by 1H2025, signaling significant potential in smart factory applications.

Elderly Care Monitoring: The report emphasizes Ainos' efforts to address Japan's aging population with an AI-driven telehealth system for long-term care facilities. The system monitors the elderly's hygiene and health by detecting VOCs linked to bowel movements and urine, with mass production also targeted for 1H2025. This program could facilitate the growing elderly care challenges in Japan's aging population. By 2040, Japan is projected to face a shortfall of approximately 570,000 caregivers, with a third of its population aged 65 and older.

Read more - https://finance.yahoo.com/news/water-tower-research-spotlights-ainos-150000620.html

I like what I am seeing.
https://finance.yahoo.com/news/ainos-achieves-major-breakthrough-japan-150000331.html

LOL...🥳...

Looks good $1.40s in the horizon I can smell it with that robot sensor

georgie18

Member Level
Re: georgie18 post# 388352

Thursday, January 23, 2025 9:28:06 AM

Post#
388939
of 388960
AIMD...70s adding here...🥳Loading under $1...

georgie18

Member Level
Re: georgie18 post# 670590

Friday, January 10, 2025 1:11:43 PM

Post#
671056
of 672094
AIMD...69...Hit $1 today...🥳

georgie18

Member Level
Re: georgie18 post# 388090

Monday, January 06, 2025 2:47:49 PM

Post#
388099
of 388351
AIMD...80s clearing here...🥳

georgie18

Member Level
Re: None

Monday, January 06, 2025 1:05:23 PM

Post#
670559
of 670589
AIMD...74s clearing here...🥳